Purpose. This analysis pooled individual patient data from randomized controlled trials (RCTs) to more thoroughly examine clinical outcomes when adding bevacizumab to chemotherapy for patients with metastatic colorectal cancer (mCRC). Patients and Methods. Patient data were pooled from the first‐line AVF2107, NO16966, ARTIST, AVF0780, AVF2192, and AGITG MAX RCTs and the second‐line E3200 RCT. All analyses were based on the intent‐to‐treat population. To assess differences in time‐to‐event variables by treatment (chemotherapy with or without placebo vs. chemotherapy plus bevacizumab), stratified random‐effects (overall) and fixed‐effects (subgroup comparisons) models were used to estimate pooled hazard ratios (HRs) and 95% confidence intervals (CIs). Results. The analysis population comprised 3,763 patients (1,773 chemotherapy with or without placebo; 1,990 chemotherapy plus bevacizumab). The addition of bevacizumab to chemotherapy was associated with statistically significant increases in overall survival (OS; HR, 0.80; 95% CI, 0.71–0.90) and progression‐free survival (PFS; HR, 0.57; 95% CI, 0.46–0.71). The effects on OS and PFS across subgroups defined by chemotherapy backbone (oxaliplatin‐based, irinotecan‐based), extent of disease (liver metastases only, extensive disease), age (<65, ≥65 years), Eastern Cooperative Oncology Group performance status (0, ≥1), and KRAS status (wild‐type, mutant) were consistent with the overall analysis. Incidence rates of grade ≥3 hypertension, proteinuria, bleeding, wound‐healing complications, gastrointestinal perforations, and thromboembolic events were increased with bevacizumab treatment. Conclusion. The use of bevacizumab with chemotherapy resulted in statistically significant increases in OS and PFS for patients with mCRC. The PFS benefit extended across the clinically relevant subgroups examined. The observed safety profile of bevacizumab was consistent with that reported in individual trials. 摘要 目的 本分析将来自随机对照试验（RCT）的贝伐珠单抗联合化疗治疗的转移性结直肠癌（mCRC）患者数据汇总至更彻底的临床结果检验中。。 患者和方法 汇总的患者数据来自一线AVF2107、NO16966、ARTIST、AVF0780、AVF2192和AGITG MAX RCT，以及二线E3200 RCT。所有分析基于意向治疗人群。按照治疗（化疗±安慰剂 vs.化疗+贝伐珠单抗）评估时间至事件变量的差异，采用分层随机效应（全体）和固定效应（亚组比较）模型估计汇总风险比（HR）和95%可信区间（CI）。 结果 分析人群包含3763例患者（化疗±安慰剂组1773例，化疗+贝伐珠单抗组1990例）。化疗+贝伐珠单抗治疗与总生存（OS；HR，0.80；95% CI，0.71 ∼ 0.90）和无进展生存（PFS；HR，0.57；95% CI，0.46 ∼ 0.71）的显著改善相关。根据基础化疗（以奥沙利铂为基础和以伊立替康为基础）定义的亚组间OS和PFS、疾病范围（仅肝转移、广泛性疾病）、年龄（<65、≥65岁）、东部肿瘤协作组体能状态（0，≥1），和KRAS状态（野生型、突变）的效应和总分析相一致。贝伐珠单抗治疗≥3级高血压、蛋白尿、出血、伤口愈合并发症、胃肠道穿孔和血栓栓塞事件的发生率升高。 结论 化疗联合贝伐珠单抗可使mCRC患者的OS和PFS显著延长。在检测的临床相关亚组中观察到广泛的PFS获益。本研究观察到的贝伐珠单抗安全性特征和单个临床研究中报告的相一致。The Oncologist 2013;18:1004‐1012 This analysis examined clinical outcomes when adding bevacizumab to chemotherapy for patients with metastatic colorectal cancer (mCRC). The use of bevacizumab with chemotherapy resulted in statistically significant increases in overall and progression‐free survival for patients with mCRC, and the observed safety profile of bevacizumab was consistent with that reported in individual trials.